Terms: = Uterine cancer AND PMS2, HNPCC4, 5395, ENSG00000122512, H_DJ0042M02_9, PMSL2, PMS2CL AND Prognosis
140 results:
1. Mismatch Repair Deficiency as a Predictive and Prognostic Biomarker in Endometrial cancer: A Review on Immunohistochemistry Staining Patterns and Clinical Implications.
Addante F; d'Amati A; Santoro A; Angelico G; Inzani F; Arciuolo D; Travaglino A; Raffone A; D'Alessandris N; Scaglione G; Valente M; Tinnirello G; Sfregola S; Padial Urtueta B; Piermattei A; Cianfrini F; Mulè A; Bragantini E; Zannoni GF
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256131
[TBL] [Abstract] [Full Text] [Related]
2. Molecular and Clinicopathologic Characterization of Mismatch Repair-Deficient Endometrial Carcinoma Not Related to MLH1 Promoter Hypermethylation.
Kaya M; Post CCB; Tops CM; Nielsen M; Crosbie EJ; Leary A; Mileshkin LR; Han K; Bessette P; de Boer SM; Jürgenliemk-Schulz IM; Lutgens L; Jobsen JJ; Haverkort MAD; Nout RA; Kroep J; Creutzberg CL; Smit VTHBM; Horeweg N; van Wezel T; Bosse T
Mod Pathol; 2024 Mar; 37(3):100423. PubMed ID: 38191122
[TBL] [Abstract] [Full Text] [Related]
3. Cervical lymphoepithelioma-like carcinoma with deficient mismatch repair and loss of SMARCA4/BRG1: a case report and five related cases.
Miyama Y; Kato T; Sato M; Yabuno A; Hasegawa K; Yasuda M
Diagn Pathol; 2024 Jan; 19(1):6. PubMed ID: 38178127
[TBL] [Abstract] [Full Text] [Related]
4. Specific Pathology Features Enrich Selection of Endometrial Carcinomas for POLE Testing.
Keyhanian K; Han L; Howitt BE; Longacre T
Am J Surg Pathol; 2024 Mar; 48(3):292-301. PubMed ID: 38062789
[TBL] [Abstract] [Full Text] [Related]
5. Conduction and validation of a novel prognostic signature in cervical cancer based on the necroptosis characteristic genes via integrating of multiomics data.
Xu T; Jiang J; Xiang X; Jahanshahi H; Zhang Y; Chen X; Li L
Comput Biol Med; 2024 Jan; 168():107656. PubMed ID: 38029530
[TBL] [Abstract] [Full Text] [Related]
6. Characteristics and outcomes of surgically staged multiple classifier endometrial cancer.
Bogani G; Betella I; Multinu F; Casarin J; GhezzI F; Sorbi F; VizziellI G; Petrillo M; Cianci S; Berretta R; PaolinI B; FanfanI F; De Vitis L; Scambia G; Mariani A; Colombo N; Raspagliesi F
Eur J Surg Oncol; 2024 Jan; 50(1):107269. PubMed ID: 37984242
[TBL] [Abstract] [Full Text] [Related]
7. Mesothelin expression in gynecologic carcinosarcoma: clinicopathological significance and correlation with HER2 expression.
Kitadai R; Nishikawa T; Yoshida H; Mizoguchi C; Yamamoto K; Kato T; Yonemori K
J Gynecol Oncol; 2024 Mar; 35(2):e11. PubMed ID: 37914528
[TBL] [Abstract] [Full Text] [Related]
8. Validation of Modaplex POLE mutation assay in endometrial carcinoma.
Dorca E; Velasco A; Varela M; Gatius S; Villatoro S; Fullana N; Cuevas D; Vaquero M; Birnbaum A; Neumann K; Matias-Guiu X
Virchows Arch; 2023 Dec; 483(6):787-794. PubMed ID: 37874375
[TBL] [Abstract] [Full Text] [Related]
9. Molecular Classification of Endometrial Endometrioid Carcinoma With Microcystic Elongated and Fragmented Pattern.
Ju B; Wu J; Sun L; Yang C; Yu H; Hao Q; Wang J; Zhang H
Int J Gynecol Pathol; 2024 May; 43(3):233-241. PubMed ID: 37733028
[TBL] [Abstract] [Full Text] [Related]
10. Genomic profile of Chinese patients with endometrial carcinoma.
Li J; Li X; Quan C; Li X; Wan C; Wu X
BMC Cancer; 2023 Sep; 23(1):888. PubMed ID: 37730563
[TBL] [Abstract] [Full Text] [Related]
11. Clinicopathologic significance of mismatch repair protein expression in endometrioid endometrial cancer.
Kim MK; So KA; Chun YK; Kim YH; Lim KT; Lee KH; Kim TJ
Taiwan J Obstet Gynecol; 2023 Sep; 62(5):724-728. PubMed ID: 37679002
[TBL] [Abstract] [Full Text] [Related]
12. p53 Immunohistochemical Staining and TP53 Gene Mutations in Endometrial cancer: Does Null Pattern Correlate With prognosis?
Sakamoto I; Kagami K; Nozaki T; Hirotsu Y; Amemiya K; Oyama T; Omata M
Am J Surg Pathol; 2023 Oct; 47(10):1144-1150. PubMed ID: 37528644
[TBL] [Abstract] [Full Text] [Related]
13. A nomogram prediction model for the TP53mut subtype in endometrial cancer based on preoperative noninvasive parameters.
Wang W; Li X; Gao Y; Zheng H; Gao M
BMC Cancer; 2023 Aug; 23(1):720. PubMed ID: 37528420
[TBL] [Abstract] [Full Text] [Related]
14. Concordance in detection of microsatellite instability by PCR and NGS in routinely processed tumor specimens of several cancer types.
Bartels S; Grote I; Wagner M; Boog J; Schipper E; Reineke-Plaass T; Kreipe H; Lehmann U
Cancer Med; 2023 Aug; 12(16):16707-16715. PubMed ID: 37376830
[TBL] [Abstract] [Full Text] [Related]
15. Pelvic Recovery After Endometrial cancer Treatment: Patient-Reported Outcomes and MRI Findings.
Maturen KE; Martin MF; Chapman CH; McLean K; Michaels BN; Uppal S; Prisciandaro JI; Wittmann DA; Jolly S
Acad Radiol; 2023 Sep; 30 Suppl 2():S202-S210. PubMed ID: 37100674
[TBL] [Abstract] [Full Text] [Related]
16. The expression of programmed death-ligand 1 and programmed death-ligand 2 in endometrial carcinosarcoma: Correlation with mismatch repair protein expression status, tumor-infiltrating lymphocyte infiltration, and clinical outcomes.
Atılgan AO; Tepeoğlu M; Özen Ö; Reyhan ANH; Ayhan A
Ann Diagn Pathol; 2023 Aug; 65():152137. PubMed ID: 37060883
[TBL] [Abstract] [Full Text] [Related]
17. [Endometrioid adenocarcinoma with proliferated stromal cells, hyalinization and cord-like formations: A case report].
Ning BH; Zhang QX; Yang H; Dong Y
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):366-369. PubMed ID: 37042152
[TBL] [Abstract] [Full Text] [Related]
18. p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study.
Köbel M; Kang EY; Weir A; Rambau PF; Lee CH; Nelson GS; Ghatage P; Meagher NS; Riggan MJ; Alsop J; Anglesio MS; Beckmann MW; Bisinotto C; Boisen M; Boros J; Brand AH; Brooks-Wilson A; Carney ME; Coulson P; Courtney-Brooks M; Cushing-Haugen KL; Cybulski C; Deen S; El-Bahrawy MA; Elishaev E; Erber R; Fereday S; ; Fischer A; Gayther SA; Barquin-Garcia A; Gentry-Maharaj A; Gilks CB; Gronwald H; Grube M; Harnett PR; Harris HR; Hartkopf AD; Hartmann A; Hein A; Hendley J; Hernandez BY; Huang Y; Jakubowska A; Jimenez-Linan M; Jones ME; Kennedy CJ; Kluz T; Koziak JM; Lesnock J; Lester J; Lubiński J; Longacre TA; Lycke M; Mateoiu C; McCauley BM; McGuire V; Ney B; Olawaiye A; Orsulic S; Osorio A; Paz-Ares L; Ramón Y Cajal T; Rothstein JH; Ruebner M; Schoemaker MJ; Shah M; Sharma R; Sherman ME; Shvetsov YB; Singh N; Steed H; Storr SJ; Talhouk A; Traficante N; Wang C; Whittemore AS; Widschwendter M; Wilkens LR; Winham SJ; Benitez J; Berchuck A; Bowtell DD; Candido Dos Reis FJ; Campbell I; Cook LS; DeFazio A; Doherty JA; Fasching PA; Fortner RT; García MJ; Goodman MT; Goode EL; Gronwald J; Huntsman DG; Karlan BY; Kelemen LE; Kommoss S; Le ND; Martin SG; Menon U; Modugno F; Pharoah PD; Schildkraut JM; Sieh W; Staebler A; Sundfeldt K; Swerdlow AJ; Ramus SJ; Brenton JD
J Pathol Clin Res; 2023 May; 9(3):208-222. PubMed ID: 36948887
[TBL] [Abstract] [Full Text] [Related]
19. Clinical characteristics and prognostic characterization of endometrial carcinoma: a comparative analysis of molecular typing protocols.
Yang Z; Yang X; Liu X; Ma K; Meng YT; Yin HF; Wen J; Yang JH; Zhen Z; Feng ZH; Liao QP
BMC Cancer; 2023 Mar; 23(1):243. PubMed ID: 36918828
[TBL] [Abstract] [Full Text] [Related]
20. Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in patients with recurrent high-grade neuroendocrine cervical cancer: a Neuroendocrine Cervical Tumor Registry (NeCTuR) study.
Frumovitz M; Chisholm GB; Jhingran A; Ramalingam P; Flores-Legarreta A; Bhosale P; Gonzales NR; Hillman RT; Salvo G
Am J Obstet Gynecol; 2023 Apr; 228(4):445.e1-445.e8. PubMed ID: 36516952
[TBL] [Abstract] [Full Text] [Related]
[Next]
